- Investing Ideas
- /
- Swedish Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
Swedish Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
Results
4
Companies with promising cash flow potential yet trading below their fair value, as determined by SWS DCF valuation, signaling opportunity for value-oriented investors.
4 companies
Bonesupport Holding
Market Cap: SEK 13.7b
An orthobiologics company, develops and sells injectable bio-ceramic bone graft substitutes in Europe, North America, and internationally.
BONEX
SEK 207.40
7D
4.3%
1Y
-41.5%
BioGaia
Market Cap: SEK 10.5b
A healthcare company, develops, manufactures, markets and sells probiotic products for gut, oral, and immune health in Europe, the Middle East, Africa, the United States, the Asia-Pacific, Australia, and New Zealand.
BIOG B
SEK 104.10
7D
5.7%
1Y
-0.3%
Camurus
Market Cap: SEK 38.4b
A biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia.
CAMX
SEK 643.50
7D
18.1%
1Y
12.9%
Vitrolife
Market Cap: SEK 19.4b
Provides assisted reproduction products in Europe, the Middle East, Africa, Asia-Pacific, and the Americas.
VITR
SEK 142.90
7D
3.0%
1Y
-35.2%